Efficacy of rTMS and VCT on Upper Limb Function in Patients With Stroke
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03350087 |
|
Recruitment Status :
Recruiting
First Posted : November 22, 2017
Last Update Posted : August 18, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cerebral Vascular Accident | Device: intermittent theta burst stimulation Device: continuous theta burst stimulation Device: iTBS+cTBS group Device: sham theta burst stimulation Device: VCT Device: VCT+optimal rTMS group | Not Applicable |
This study aims to 1. identify the immediate effects of different treatment protocols in for UE training in these patients through brain image, motor control and clinical measures; 2. to determine the maintaining therapeutic effects; 3. to elucidate the most optimal treatment protocols; 4. to determine the neuro-motor control mechanism underlying clinical improvement; 5. to determine the clinimetric properties of the brain imaging and motor control measure that are responsive and valid for detecting changes after treatment protocol intervention, and 6. to identify clinical predictors influencing the outcome for treatment protocols.
The research will offer valuable motor control biomarkers for outcome prediction and targeting patients who benefit from new protocols. This project is significant for the translational and evidence-based medicine on stroke neurorehabilitation.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 120 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Efficacy of Repetitive Transcranial Magnetic Stimulation and Virtual Cycling Training on Upper Limb Function in Patients With Stroke |
| Actual Study Start Date : | August 2016 |
| Estimated Primary Completion Date : | February 11, 2022 |
| Estimated Study Completion Date : | May 31, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: iTBS group
In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
|
Device: intermittent theta burst stimulation
In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total) Other Names: intermittent theta burst stimulation |
|
Experimental: cTBS group
In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
|
Device: continuous theta burst stimulation
In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total). Other Names: continuous burst stimulation |
|
Experimental: iTBS+cTBS group
Continuous theta burst stimulation (cTBS group) at first followed by intermittent theta burst stimulation (iTBS group).
|
Device: iTBS+cTBS group
In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total) |
|
Sham Comparator: sham TBS group
In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
|
Device: sham theta burst stimulation
In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total). Other Names: sham theta burst stimulation |
|
Experimental: VCT group
VCT group received the VCT training in addition to traditional rehabilitation. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
|
Device: VCT
The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body. Other Names: The upper extremity programs virtual cycling training program |
|
Experimental: VCT+optimal rTMS group
VCT+optimal rTMS group received the VCT training and optimal rTMS in addition to traditional rehabilitation.
|
Device: VCT+optimal rTMS group
In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1. |
- Change from baseline of mechanical measurement for stroke after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Kinematic analysis for upper limb
- Change from baseline of severity for stroke after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Brunnstrom stage classification(by severity from stage 1 to stage 6), Modified Ashworth Scale (tension of upper limb from min(0) to max (4)) and National Institute of Health Stroke Scale (severity from min(0) to max(4))
- Change from baseline of Muscle tone measurement for stroke after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Muscle tone
- Change from baseline of Muscle strength measurement for stroke after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Muscle strength
- Change from baseline of body composition for stroke in after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]InBodyS10 Body Composition Analyzer
- Change from baseline of activity for stroke in after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Barthel Index
- Change from baseline of ABAS for stroke in after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Adaptive behavior assessment system
- Change from baseline of quality of life for stroke in after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Stroke Impact Scale
- Change from baseline of WMFT for stroke in after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Wolf motor function test
- Change from baseline of MAL for stroke in after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Motor activity log
- Change from baseline of TUG for stroke in after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Timed 'Up & Go' test
- Change from baseline of FIM for stroke in after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Functional Independence Measure
- Change from baseline of participation for stroke in after 3 weeks treatment and 3 months follow-up [ Time Frame: baseline, after 3 weeks of treatment, 3 months ]Nottingham Health Profile
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- first stroke
- chronic stroke (onset > 3 months)
- unilateral cerebral lesion with hemiparesis or hemiplegia
- age of 20-80 years
- no epileptic spikes on the EEG
Exclusion Criteria:
- brain stem or cerebellum stroke
- epilepsy
- aneurysm
- arteriovenous malformation
- psychiatric disease
- degenerative disease
- severe cognitive and communicative impairment or aphasia
- severe medical disease
- active medical problems
- metal implant in the body
- pregnancy
- poor cooperation with assessments
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03350087
| Contact: Chia-Ling Chen, MD, PhD | +886-3-3281200 ext 8148 | clingchen@gmail.com |
| Taiwan | |
| Chang Gung Memorial Hospital | Recruiting |
| Taoyuan, Taiwan, 333 | |
| Contact: Chia-Ling Chen, MD, PhD +886-3-3281200 ext 8147 clingchen@gmail.com | |
| Principal Investigator: Chia-Ling Chen, MD, PhD | |
| Study Director: | Chia-Ling Chen, MD, PhD | Chang Gung Memorial Hospital |
| Responsible Party: | Chang Gung Memorial Hospital |
| ClinicalTrials.gov Identifier: | NCT03350087 |
| Other Study ID Numbers: |
104-8816A3 |
| First Posted: | November 22, 2017 Key Record Dates |
| Last Update Posted: | August 18, 2020 |
| Last Verified: | January 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
repetitive transcranial magnetic stimulation stroke optimal treatment protocol VR-based cycling training (VCT) |
randomized controlled trial motor control clinical predictors |
|
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |

